Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
about
T lymphocytes targeting native receptorsEmerging treatment options for nasopharyngeal carcinomaNovel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccineFunctional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapyHumoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersEvaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vectorT cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo.Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies.Improving T cell therapy for cancer.Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinomaSystemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapyExpansion and activation of natural killer cells for cancer immunotherapy.Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.Peculiar features and tailored management of adult cancers occurring in pediatric age.Immunotherapy for EBV-associated malignancies.Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens.Prognostic aspects in the treatment of juvenile nasopharyngeal carcinoma: a systematic review.Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.T cell therapy for nasopharyngeal carcinoma.T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results.A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project.Locoregionally advanced nasopharyngeal carcinoma in childhood and adolescence: Analysis of 95 patients treated with combined chemotherapy and intensity-modulated radiotherapy.Adoptive cell therapy against EBV-related malignancies: a survey of clinical resultsTreatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells
P2860
Q26853345-7C8CDB14-32A1-48A5-AEEC-E86D8123F28EQ26995560-0E78917E-03FF-496F-B4B5-947E99BA70D3Q28749468-C11DF829-B871-40B5-84A4-60CC1E81C817Q33305203-8902F5B7-B4C0-4345-8104-9FACBBA52760Q33822681-D8FBC9AE-0DB7-484B-87DB-CF0A0D944CDFQ34166602-AACA14CC-4A12-48FB-B3B4-E77F62AE8DB8Q35238310-B23712DC-BFC9-43C2-9F48-B912B89272D8Q35483599-AEDE7028-5591-469F-8AFB-BC0B635878C3Q35507358-F0911DBE-0498-41D8-9953-447C149F9546Q35594089-DEFDBDAC-95BF-4B77-855E-C99A748CD206Q35670921-A510767A-5FBB-4430-9784-A96C88838355Q35815850-93ADEE33-5FE0-4DA7-98B5-00F2C8632697Q36303951-73F1BEB3-E752-485B-879C-9F7BAC1CE386Q36407236-5822C9C9-CD11-44B9-B2C9-C45E987054BCQ37117769-8F51200F-8A37-46BB-B446-5864B47947A2Q37171008-8211B91F-0E3A-4EF7-A113-ABF8AC74DBE1Q37183682-663BBD4D-007D-45CD-9D31-FC727BAB2800Q37408279-5D5AB8CA-5AED-4408-87E9-A703FEBB1043Q37705026-23AE2E33-B785-4243-9489-5C1ABE37B0CEQ37809864-F48C1180-EDD7-4521-8055-4B2FFCE2C7E3Q37845178-B563A9C3-88E7-4444-97D3-6E552176599CQ38570061-0199C625-6CBB-416E-80DC-F547617D70FBQ38869467-B3E05F0D-2F3C-4F49-AF79-40C623E57342Q40323714-F1CD2DD7-BE8F-44E9-95C1-E73C8D5300D0Q42170835-46E0535A-69D0-491F-B654-6E81839585F1Q42766336-5D91A8C6-AC24-454E-B3D0-1522FBCFFD09Q44267072-1BD0D9C6-70EC-40EF-9C11-A630EB7F42E1Q44879910-883A320B-95F7-4E73-A7BC-3B0D086B34DEQ50352713-9AFB7039-A399-4007-BD1D-4BFD9E6FEAAEQ57056125-0CED1614-485C-4773-8F40-5807EC86194AQ57275304-A7845259-67FE-4C0C-9D2C-4887833DDF73
P2860
Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Adoptive transfer of allogenei ...... ated nasopharyngeal carcinoma.
@en
Adoptive transfer of allogeneic Epstein-Barr virus
@nl
type
label
Adoptive transfer of allogenei ...... ated nasopharyngeal carcinoma.
@en
Adoptive transfer of allogeneic Epstein-Barr virus
@nl
prefLabel
Adoptive transfer of allogenei ...... ated nasopharyngeal carcinoma.
@en
Adoptive transfer of allogeneic Epstein-Barr virus
@nl
P2093
P50
P921
P356
P1433
P1476
Adoptive transfer of allogenei ...... lated nasopharyngeal carcinoma
@en
P2093
A Tagliamacco
F Del Galdo
F Locatelli
G F Abbate
O Carminati
R Maccario
P304
P356
10.1093/ANNONC/MDH027
P577
2004-01-01T00:00:00Z